In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Institutionalizing Externalization At Big Pharma – The Third Leg

Executive Summary

The pharmaceutical industry has a hard time saying goodbye to strategic assets. In fact, it’s much more adept at welcoming new ones: diversification – either geographic or into areas beyond pure-play pharmaceuticals – has become commonplace. But pharma needs to overcome its entrenched resistance to asset externalization, which should become a critical third leg in its attempts to build long-term shareholder value. Strategic, almost biotech-like externalization strategies should move from a peripheral to a core part of pharma’s activities. Why haven’t they already been embraced?

Advertisement

Related Content

Biogen Idec Buys Stromedix, Bringing IPF Candidate Full Circle
Biopharma Out-licensing: 2012’s “In” Thing?
Merck's Capital Idea: Industry's Latest Push to Strengthen VC Ties
Atlas, CMEA Test New Biotech Model
With Pharma Ready to Pare Portfolios, Project Financing Funds Make Their Pitches
GSK's Virtual-Proof-of-Concept Unit in Tune with Lilly's Chorus
Novartis Plans To Buy Back Speedel For $880 Million
Lilly's Chorus Experiment
Movetis Takes GI from J&J
Synosis: the Financial Leverage of Translational Medicine

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003816

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel